Related references
Note: Only part of the references are listed.Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Chipman R. G. Stroud et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Management of Immunotherapy-Related Toxicities. Version 1.2019
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
Filipe Martins et al.
LANCET ONCOLOGY (2019)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy
Alice Horisberger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab
Dagur Ingi Jonsson et al.
NEUROMUSCULAR DISORDERS (2017)
Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy
Nada Hradilova et al.
PLOS ONE (2017)
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
Ashley M. Hopkins et al.
BRITISH JOURNAL OF CANCER (2017)
Immune-based Therapies for Non-small Cell Lung Cancer
Hind Rafei et al.
ANTICANCER RESEARCH (2017)
Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno et al.
BLOOD (2016)
Quality of Life in Patients With Advanced Cancer: Differential Association With Performance Status and Systemic Inflammatory Response
Barry J. A. Laird et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Systemic inflammatory response syndrome (SIRS) with immune checkpoint inhibitors
Nitika Sharma et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
LAP TGF-beta subset of CD4+CD25+CD127-Treg cells is increased and overexpresses LAP TGF-beta in lung adenocarcinoma patients
L. Islas-Vazquez et al.
EUROPEAN JOURNAL OF CANCER (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Prognostic value of circulating inflammatory factors in non-small cell lung cancer: A systematic review and meta-analysis
Chen Liao et al.
CANCER BIOMARKERS (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer
C. Bodelon et al.
ANNALS OF ONCOLOGY (2013)
Possible Role for Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, in Treating Cancer Cachexia
Katsutoshi Ando et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer
Trevor J. Bayliss et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Increased Levels of Circulating Interleukin 6, Interleukin 8, C-Reactive Protein, and Risk of Lung Cancer
Sharon R. Pine et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Efficacy of Tocilizumab in Two Patients with anti-TNF-alpha Refractory Uveitis
Aurore Muselier et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2011)
A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature
Katja Perdan-Pirkmajer et al.
CLINICAL RHEUMATOLOGY (2010)
Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor
Jean-Michel Dayer et al.
RHEUMATOLOGY (2010)
Serum Concentrations of Cytokines and Lung Cancer Survival in African Americans and Caucasians
Lindsey Enewold et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Interleukin-6 and its receptor in cancer - Implications for translational therapeutics
David S. Hong et al.
CANCER (2007)
Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer
EB Haura et al.
CLINICAL CANCER RESEARCH (2005)
Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer
EB Haura et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2005)
An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer
FM Brichory et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)